Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrium Medical Corp.
Licensing deal signed for use of TAFA93 and ISA247 with medical devices
November 4th, 2005
Atrium Medical Corp. and Isotechnika, Inc., jointly announced the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting devices for the local, non-systemic treatment of vascular and cardiovascular disorders, soft tissue repair, and a variety of other uses related to Atrium's implantable products. TAFA93 is a novel prodrug of rapamycin (an mTOR inhibitor) with powerful anti-proliferative effects similar to several other known mTOR inhibiting compounds but with improved pharmacokinetic properties. Atrium has demonstrated a significant biological effect in our preclinical drug eluting coronary stent models...
Source: Biotech Law Weekly (2005-11-04)
|
